Recent presentations

ASCO abstracts 2015

  1. ​Ulrik Niels Lassen, Morten Mau-Soerensen, Andrew L. Kung, Patrick Y. Wen, Eudocia Quant Lee, Scott R. Plotkin, Aida Muhic, Tami Rashal, Tony Williams, Dilara McCauley, Joel Ellis, Jean-Richard Saint-Martin, Robert Carlson, Ran Frenkel, Sharon Shacham, Mansoor Raza Mirza, Michael Kauffman, Andrew B.  Lassman. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J Clin Oncol 33, 2015 (suppl; abstr 2044)

  2. Ulrik Niels Lassen, David S. Hong, Nikolaos Diamantis, Vivek Subbiah, Rajiv Kumar, Morten Sorensen, Steen Lisby, Robert L. Coleman, Johann Sebastian De Bono. A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors. ​J Clin Oncol 33, 2015 (suppl; abstr 2570)

  3. Jan H. M. Schellens, Josep Tabernero, Ulrik Niels Lassen, Ignacio Melero, Krisztian Homicsko, Guillem Argilés, Jose Luis Perez Gracia, Morten Sorensen, George Coukos, ERIC ANGEVIN, Heikki Joensuu, Emilie Van Brummelen, Catharina Wilhelmina Menke, Tapan K. Nayak, Solange Romagnoli, Bernhard Reis, Sophia Soehrman Brossard, Stefan Evers, Jose M. Saro Suarez, Henk M.W. Verheul. CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. J Clin Oncol 33, 2015 (suppl; abstr 3016)

  4. Elizabeth R. Plummer, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Heinrich Maria Jerusalem, Christian D. Rolfo, Dorte L. Nielsen, L Rhoda Molife, Rebecca Kristeleit, Judith de Vos-Geelen, Morten Mau-Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Helen Swaisland, Anitra Fielding, Karen So, Wendy Bannister, Luc Dirix. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies. J Clin Oncol 33, 2015 (suppl; abstr 2565)

Presentations ASCO-GI 2014

  1. Safety and anti-tumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export - a phase I study expanded with colon cancer cohort. Morten Mau-Soerensen, Albiruni R A Razak, Amit Mahipal, Hemchandra Mahaseth, John F. Gerecitano, Sharon Shacham, Cindy Y. F. Yau, Ulrik Lassen, Anthony Frank Shields, Dilara McCauley, Jennifer Cooksey, David Shao Peng Tan, Tami Rashal, Eran Shacham, Yosef Landesman, Gregory Pond, Amit M. Oza, Michael Kauffman, Lillian Siu, Mansoor Raza Mirza​

Presentations ASCO 2014

  1. A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. Morten Mau-Soerensen, Albiruni R. A. Razak, Anthony Frank Shields, Nashat Y. Gabrail, John F. Gerecitano, Sharon Shacham, Ulrik Niels Lassen, Tami Rashal, Jennifer Cooksey, Yosef Landesman, Gregory Pond, Amit M. Oza, Michael Kauffman, Lillian L. Siu, Philippe L. Bedard, Hemchandra Mahaseth, Mansoor Raza Mirza, Amit Mahipal. J Clin Oncol 32:5s, 2014 (suppl; abstr 2537)

  2. Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum. Morten Mau-Soerensen, Olfred Hansen, Bente Holm, Christa Haugaard Nyhus, Tine McCulloch, Henrik Anker Nielsen, Kim Wedervang, Carsten Rytter, Nina Jeppesen, Seppo Langer. J Clin Oncol 32:5s, 2014 (suppl; abstr 7519

  3. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML). Karen W. L. Yee, Michael Savona, Morten Sorensen, Peter Brown, William G. Blum, Daniel J. DeAngelo, Martin Gutierrez, Ramiro Garzon, Andre C. Schuh, Nashat Y. Gabrail, Martha Wadleigh, Jeffrey E. Lancet, Bijal D. Shah, Jesus G. Berdeja, Nina D. Wagner-Johnston, Ian Flinn, Tami Rashal, Michael Kauffman, Sharon Shacham, Richard M. Stone. J Clin Oncol 32:5s, 2014 (suppl; abstr 7032)

  4. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL). Martin Gutierrez, Andre Goy, John C. Byrd, Joseph M. Flynn, Morten Sorensen, Peter Brown, Nashat Y. Gabrail, Michael Savona, Ian Flinn, Rachid C. Baz, Bijal D. Shah, Richard M. Stone, Eric Jacobsen, Vishal Kukreti, Roger E. Tiedemann, Tami Rashal, Mansoor Raza Mirza, Sharon Shacham, Michael Kauffman, John Kuruvilla; John J Clin Oncol 32:5s, 2014 (suppl; abstr 8518)

  5. Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial. Ulrik Niels Lassen, Steen Knudsen, Pernille Braemer Hertel, Iben Kumler, Dorte Nielsen, Bent Ejlertsen, Morten Mau Soerensen, Nils Brunner, Ulla Hald Buhl, Mogens Winkel Madsen, Ida Kappel Buhl, Anker Hansen, Thomas Jensen, Eva Balslev, Jon Askaa, Peter Michael Vestlev, Anne-Vibeke Laenkholm, Peter Buhl Jensen. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1139)

  6. Copenhagen Prospective Personalized Oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to Phase 1 studies. Ida Elisabeth Viller Tuxen, Eric Santoni-Rugiu, Lars Joenson, Jonas Vikesaa, Morten Mau-Soerensen, Finn Cilius Nielsen, Ulrik Niels Lassen J Clin Oncol 32:5s, 2014 (suppl; abstr 11097)

  7. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). Henk M. Lokhorst, Jacob Laubach, Hareth Nahi, Torben Plesner, Peter Gimsing, Markus Hansson, Monique Minnema, Ulrik Niels Lassen, Jakub Krejcik, Tahamtan Ahmadi, Steen Lisby, Linda Basse, Nikolai C. Brun, Paul G. Richardson. J Clin Oncol 32:5s, 2014 (suppl; abstr 8513)

  8. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Torben Plesner, Hendrik-Tobias Arkenau, Henk M. Lokhorst, Peter Gimsing, Jakub Krejcik, Charlotte Rose Lemech, Monique Minnema, Ulrik Niels Lassen, Tahamtan Ahmadi, Howard Yeh, Mary Guckert, Nikolai C. Brun, Steen Lisby, Linda Basse, Antonio Palumbo, Paul G. Richardson. J Clin Oncol 32:5s, 2014 (suppl; abstr 8533)

  9. Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. Pilar Garrido Lopez, Enriqueta Felip, Jean-Pierre Delord, Luis Paz-Ares, Juneko E. Grilley-Olson, Michael S. Gordon, Fabrice Barlesi, Hendrik-Tobias Arkenau, Primo Lara, Paul K. Paik, Daniel Morgensztern, Shirish M. Gadgeel, Karen L. Reckamp, Erin Marie Bertino, Sergey Orlov, Eugeny Levchenko, Ignacio Delgado, Jose Manuel Trigo Perez, Teresa Moran, Ulrik Niels Lassen. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8120)

Presentations ESMO 2014


  1. Phase Ib trial trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in combination with cetuximab or erlotinib in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. U. Lassen, A. Cervantes Ruiperez, T. Fleitas, D. Meulendijks, J. Schellens, M. Lolkemar, M. J. De Jonge, S. Sleijfer, M. Mau-Soerensen, A. Taus, C. Adessi, A. Keelara, F. Michielin, B. Bossenmaier, G. Meneses-Lorente, I. James, W. Jacob, M. Weisser, M. Martinez-Garcia. Ann Oncol (2014) 25 (suppl 4): iv147 doi:10.1093/annonc/mdu331.4

Presentations ASCO 2013

  1. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. Henk M Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique Minnema, Ulrik Niels Lassen, Jakub Krejcik, Jacob Laubach, Steen Lisby, Linda Basse, Paul Gerard Guy Richardson. J Clin Oncol 31, 2013 (suppl; abstr 8512)

  2. First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. Albiruni R A Razak, Morten Mau Soerensen, Amit Mahipal, Sharon Shacham, Cindy Y. F. Yau, Ulrik Niels Lassen, Dilara McCauley, Jennifer Cooksey, David Shao Peng Tan, Jean-Richard Saint-Martin, Yossi Landesman, Gregory Pond, Amit M. Oza, Michael Kauffman, Lillian L. Siu, Mansoor Raza Mirza. J Clin Oncol 31, 2013 (suppl; abstr 2505)

  3. A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. Didier Meulendijks, Martijn P. J. K. Lolkema, Emile E. Voest, Maja J. De Jonge, Stefan Sleijfer, Jan HM Schellens, Tania Fleitas, Andres Cervantes-Ruiperez, Maria Martinez-Garcia, Alvaro Taus, Morten Mau Soerensen, Marlene Thomas, Georgina Meneses-Lorente, Celine Adessi, Lilla Di Scala, Abiraj Keelara, Wolfgang Jacob, Martin Weisser, Ulrik Niels Lassen. J Clin Oncol 31, 2013 (suppl; abstr 2522)

  4. Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM). Ulrik Niels Lassen, Oliver L. Chinot, Catherine McBain, Morten Sorensen, Vibeke Andree Larsen, Maryline Barrie, Patrick Roth, Oliver Krieter, Karen Wang, Kai Habben, Jean Tessier, Angelika Lahr, Matt Whiley, Michael Weller; Rigshospitalet, Copenhagen, Denmark. J Clin Oncol 31, 2013 (suppl; abstr 2092)

Responsible editor